These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 27140983

  • 21. Wild-card patent extensions as a means to incentivize research and development of antibiotics.
    Sonderholm J.
    J Law Med Ethics; 2009; 37(2):240-6. PubMed ID: 19493069
    [Abstract] [Full Text] [Related]

  • 22. Seeking innovation: incentive funding for biodefense biotechs.
    Nolan JM, Samad EU, Jindra LF, Brozak SG.
    Biosecur Bioterror; 2010 Dec; 8(4):365-72. PubMed ID: 21142763
    [Abstract] [Full Text] [Related]

  • 23. Pay drug companies $1bn for each new antibiotic, says report.
    Owen J.
    BMJ; 2016 May 19; 353():i2863. PubMed ID: 27198868
    [No Abstract] [Full Text] [Related]

  • 24. R&D: Antibiotic partners promote discovery.
    Bakken JS.
    Nature; 2016 Sep 08; 537(7619):167. PubMed ID: 27604939
    [No Abstract] [Full Text] [Related]

  • 25. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP, Singh SC, Brennan TA.
    Health Aff (Millwood); 2015 Feb 08; 34(2):294-301. PubMed ID: 25646110
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Report calls for $2bn global fund to kickstart antibiotic development.
    Wise J.
    BMJ; 2015 May 14; 350():h2635. PubMed ID: 25975228
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations.
    Hey SP, Kesselheim AS.
    Hastings Cent Rep; 2017 Mar 14; 47(2):16-20. PubMed ID: 28301705
    [Abstract] [Full Text] [Related]

  • 31. The changing environment for technological innovation in health care.
    Goodman CS, Gelijns AC.
    Baxter Health Policy Rev; 1996 Mar 14; 2():267-315. PubMed ID: 11066263
    [Abstract] [Full Text] [Related]

  • 32. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.
    Ridley DB, Sánchez AC.
    Lancet; 2010 Sep 11; 376(9744):922-7. PubMed ID: 20833303
    [Abstract] [Full Text] [Related]

  • 33. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C.
    Food Drug Law J; 2011 Sep 11; 66(3):417-78, iii. PubMed ID: 24505856
    [Abstract] [Full Text] [Related]

  • 34. [Why are new drugs so expensive?].
    Le Galès C.
    Med Sci (Paris); 2018 Apr 11; 34(4):354-361. PubMed ID: 29658480
    [Abstract] [Full Text] [Related]

  • 35. Incentives for biodefense countermeasure development.
    Matheny J, Mair M, Mulcahy A, Smith BT.
    Biosecur Bioterror; 2007 Sep 11; 5(3):228-38. PubMed ID: 17903091
    [Abstract] [Full Text] [Related]

  • 36. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J, Smith B, Courtney B, Mair M.
    Clin Pharmacol Ther; 2009 Jun 11; 85(6):571-2. PubMed ID: 19451907
    [No Abstract] [Full Text] [Related]

  • 37. Inadequately met needs.
    Nat Biotechnol; 2011 May 11; 29(5):371. PubMed ID: 21552219
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.
    Cockburn I, Long G.
    Expert Opin Ther Pat; 2015 Jul 11; 25(7):739-42. PubMed ID: 25927945
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.